Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy.

Literature DB >> 17547849

Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy.

Man Mohan Mehndiratta¹, Avinash Chandra Singh.

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder characterized by progressive or relapsing symmetrical motor or sensory symptoms and signs in more than one limb, developing over at least 2 months. It may cause prolonged periods of disability and even death. Evidence from trials suggests that plasma exchange provides significant short-term benefit in about two thirds of patients with chronic inflammatory demyelinating polyradiculoneuropathy. This review evaluates the role of plasmapheresis in CIDP.

Entities: Disease Species

Mesh：

Year: 2007 PMID： 17547849 DOI： 10.1007/s11882-007-0041-z

Source DB: PubMed Journal: Curr Allergy Asthma Rep ISSN： 1529-7322 Impact factor: 4.806

38 in total

1. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients.

Authors: A Sghirlanzoni; A Solari; C Ciano; C Mariotti; E Fallica; D Pareyson
Journal: Neurol Sci Date: 2000-02 Impact factor: 3.307

2. Chronic inflammatory polyradiculoneuropathy.

Authors: P J Dyck; A C Lais; M Ohta; J A Bastron; H Okazaki; R V Groover
Journal: Mayo Clin Proc Date: 1975-11 Impact factor: 7.616

Review 3. Immunosuppressive agents and plasmapheresis in immunological disorders.

Authors: G C Tsokos; J E Balow
Journal: J Immunopharmacol Date: 1985

4. Treating chronic relapsing Guillain-Barré syndrome by plasma exchange.

Authors: R L Levy; R Newkirk; J Ochoa
Journal: Lancet Date: 1979-08-04 Impact factor: 79.321

5. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors: J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal: Neurology Date: 2001-02-27 Impact factor: 9.910

6. Chronic relapsing polyneuritis.

Authors: J W Prineas; J G McLeod
Journal: J Neurol Sci Date: 1976-04 Impact factor: 3.181

7. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

Authors: A F Hahn; C F Bolton; N Pillay; C Chalk; T Benstead; V Bril; K Shumak; M K Vandervoort; T E Feasby
Journal: Brain Date: 1996-08 Impact factor: 13.501

8. Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy.

Authors: P A van Doorn; A Brand; M Vermeulen
Journal: Neurology Date: 1987-11 Impact factor: 9.910

9. Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy.

Authors: M B Bromberg; E L Feldman; S Jaradeh; J W Albers
Journal: J Clin Epidemiol Date: 1992-01 Impact factor: 6.437

10. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Authors: M Vermeulen; P A van Doorn; A Brand; P F Strengers; F G Jennekens; H F Busch
Journal: J Neurol Neurosurg Psychiatry Date: 1993-01 Impact factor: 10.154

3 in total